Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Neurotech’s (ASX:NTI) vital approval to start its human pharmacokinetic study in Adelaide.

The company’s oral cannabinoid drug NTI164 is being developed as a therapeutic drug product for a range of neurological disorders where neuroinflammation is involved.

Tune in to get the latest.

 

While Neurotech is a Stockhead advertiser, it did not sponsor this content.

Read MoreHealth

Featured Companies

You might be interested in